Given that the execs of alterity have all worked and sold a neuro drug too Teva therapeutics. I went to see if there was any association "sneakily" with Alterity.
Although I could not see any current association, I did notice that Teva were also looking into treating MSA with their own product.
The benefit for Alterity is that we are weeks away from ending our phase 2 study, and Teva is just beginning there phase 2 study which will end late 2027.
Interestingly enough, they had a study below showing that interfering with a-syn aggregation showed an increase in anti melanoma immune responses.
Could this possibly be an extra treatment for ATH434 ???.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)